Crizotinib inhibits activation of MET pathway caused by MET extracellular SEMA domain duplication

Jiatong Lin,Yingcheng Lyu,Lin Li,Duoguang Wu,Jiewen Chen,Tengjiao Lin, Zhan Huang,Jinwei Hu,Wenjing Wang,Huayue Lin,Minghui Wang

Lung Cancer（2020）

引用 0|浏览26

暂无评分

摘要

•A novel MET SEMA domain duplication was identified in a non-small cell lung cancer patient.•Off-label use of the kinase inhibitor crizotinib led to a marked response of the patient.•Cellular analyses provide a functional basis for the oncogenic role of the structural MET alteration.•The novel MET mutation may represent actionable targets in lung cancer patients.

查看译文

关键词

MET mutation,Next-generation sequencing,Targeted therapy,Crizotinib,Non-small cell lung cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要